Last reviewed 2026-04-20 · How we verify

Trichonat (HACHIMYCIN)

Phase 2 active

Trichonat (generic name: HACHIMYCIN) is a hachimycin drug. It is currently in Phase 2 development for Candidiasis, Infection by Trichomonas.

Hachimycin works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.

Trichonat (Hachimycin) is a small molecule antibiotic in the hachimycin class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat Candidiasis and Infection by Trichomonas. The commercial status of Trichonat is unknown, and it may be patented or generic. Key safety considerations are not well-documented. Trichonat is used to treat infections caused by certain types of fungi and protozoa.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HACHIMYCIN
Drug class	hachimycin
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells as strong, protective walls. Hachimycin disrupts the way these walls are built, causing them to break down and leading to the death of the cells. This helps to eliminate the infection.

Approved indications

Candidiasis
Infection by Trichomonas

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Trichonat CI brief — competitive landscape report
Trichonat updates RSS · CI watch RSS

Frequently asked questions about Trichonat

What is Trichonat?

Trichonat (HACHIMYCIN) is a hachimycin drug, indicated for Candidiasis, Infection by Trichomonas.

How does Trichonat work?

Hachimycin works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.

What is Trichonat used for?

Trichonat is indicated for Candidiasis, Infection by Trichomonas.

What is the generic name of Trichonat?

HACHIMYCIN is the generic (nonproprietary) name of Trichonat.

What drug class is Trichonat in?

Trichonat belongs to the hachimycin class. See all hachimycin drugs at /class/hachimycin.

What development phase is Trichonat in?

Trichonat is in Phase 2.

Drug class: All hachimycin drugs
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Candidiasis
Indication: Drugs for Infection by Trichomonas

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing